Immunohistochemical analysis of tumor budding as predictor of lymph node metastasis from superficial esophageal squamous cell carcinoma.
Aged
Aged, 80 and over
Epithelial Cells
/ metabolism
Esophageal Neoplasms
/ pathology
Esophageal Squamous Cell Carcinoma
/ secondary
Female
Humans
Immunohistochemistry
/ methods
Keratins
/ metabolism
Lymph Nodes
/ metabolism
Lymphatic Metastasis
/ pathology
Male
Middle Aged
Neoplasm Grading
/ methods
Predictive Value of Tests
ROC Curve
Retrospective Studies
Staining and Labeling
/ methods
Tumor Burden
Esophageal squamous cell carcinoma
Immunohistochemistry
Lymph node metastasis
Tumor budding
Journal
Esophagus : official journal of the Japan Esophageal Society
ISSN: 1612-9067
Titre abrégé: Esophagus
Pays: Japan
ID NLM: 101206627
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
18
06
2019
accepted:
01
10
2019
pubmed:
9
10
2019
medline:
15
7
2021
entrez:
10
10
2019
Statut:
ppublish
Résumé
Tumor budding is known predictors of lymph node metastasis from esophageal squamous cell carcinoma. However, it is not easy to detect such small cell clusters on hematoxylin-eosin (HE) staining. Therefore, we evaluated tumor budding using immunohistochemistry (IHC) for epithelial cell markers. We analyzed tumor budding in 50 cases of superficial esophageal squamous cell carcinoma. We evaluated the impact of clinicopathological factors and tumor budding to predict lymph node metastasis. A total of 565 tumor sections were assessed using HE staining and IHC for cytokeratin 5/6. Based on receiver operating characteristic curves, the cut-off values for high-grade tumor budding evaluated using HE staining or IHC were 2 and 11, respectively. High-grade tumor budding evaluated using HE staining (P = 0.007) and IHC (P ≤ 0.001) were significantly correlated with lymph node metastasis. For tumors with pT1a-MM to pT1b-SM1, high-grade tumor budding evaluated using IHC was correlated with lymph node metastasis (P = 0.050). Tumor budding was significantly associated with lymph node metastasis. The optimal cut-off values of tumor budding on HE staining and tumor budding on IHC were 2 and 11, respectively. Even though both tumor budding on HE staining and tumor budding on IHC were significantly associated with lymph node metastasis, tumor budding on IHC tend to be more associated with lymph node metastasis.
Sections du résumé
BACKGROUND
Tumor budding is known predictors of lymph node metastasis from esophageal squamous cell carcinoma. However, it is not easy to detect such small cell clusters on hematoxylin-eosin (HE) staining. Therefore, we evaluated tumor budding using immunohistochemistry (IHC) for epithelial cell markers.
METHOD
We analyzed tumor budding in 50 cases of superficial esophageal squamous cell carcinoma. We evaluated the impact of clinicopathological factors and tumor budding to predict lymph node metastasis. A total of 565 tumor sections were assessed using HE staining and IHC for cytokeratin 5/6.
RESULTS
Based on receiver operating characteristic curves, the cut-off values for high-grade tumor budding evaluated using HE staining or IHC were 2 and 11, respectively. High-grade tumor budding evaluated using HE staining (P = 0.007) and IHC (P ≤ 0.001) were significantly correlated with lymph node metastasis. For tumors with pT1a-MM to pT1b-SM1, high-grade tumor budding evaluated using IHC was correlated with lymph node metastasis (P = 0.050).
CONCLUSIONS
Tumor budding was significantly associated with lymph node metastasis. The optimal cut-off values of tumor budding on HE staining and tumor budding on IHC were 2 and 11, respectively. Even though both tumor budding on HE staining and tumor budding on IHC were significantly associated with lymph node metastasis, tumor budding on IHC tend to be more associated with lymph node metastasis.
Identifiants
pubmed: 31595396
doi: 10.1007/s10388-019-00698-5
pii: 10.1007/s10388-019-00698-5
doi:
Substances chimiques
Keratins
68238-35-7
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
168-174Références
Esophagus. 2017;14(1):1-36
pubmed: 28111535
Cancer. 2009 Jul 15;115(14):3324-34
pubmed: 19452547
Ann Surg Oncol. 2008 Jul;15(7):1977-82
pubmed: 18408975
Mod Pathol. 2017 Sep;30(9):1299-1311
pubmed: 28548122
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Anticancer Res. 2013 Nov;33(11):5023-9
pubmed: 24222146
J Surg Oncol. 2013 Jul;108(1):42-6
pubmed: 23609421
Ann Gastroenterol Surg. 2017 Dec 19;2(1):6-12
pubmed: 29863118
Int J Clin Oncol. 2018 Feb;23(1):1-34
pubmed: 28349281